Therapeutic swabs for treating upper respiratory infections
OwnerSubhash Dhawaninventor
Life of this patent
Estimating the term…
Abstract
Compounds and methods for preventing or treating upper respiratory virus infections in humans and animal species are disclosed. The compounds may exhibit antimicrobial, antiviral, anti-inflammatory, anticoagulant or cytoprotective activities. The methods may deliver compounds to be delivered to the nasal and oral cavities, nasopharynx, and posterior pharynx, the primary sites of upper respiratory infections, such as influenza, SARS, and SARS-CoV-2. Therapeutic swabs comprising one or more compounds are may be used to deliver one or more compounds to deliver the above primary sites of the individuals infected with one or more upper respiratory viruses or other pathogens.
Claims23
A therapeutic swab consisting of:
- a stem having a first end and a second end;
- a first drug-loaded swab located at the first end, the first drug-loaded swab consisting of a swab and a first plurality of drugs consisting of a first composition consisting of:
- at least one antiviral agent,
- at least one heme oxygenase-1 (HO-1) inducer selected from the group consisting of hemin, 4-octyl-itaconate, dimethyl fumarate, and combinations thereof,
- an anticoagulant selected from a modified heparin, a low molecular weight heparin (LMWH), chondroitin sulfate (CS), and a modified glycosaminoglycans (GAG) derivative, and
- a drug component having anti-inflammatory activity;
- and
- a second drug-loaded swab located at the second end, wherein the second drug-loaded swab consists of a second plurality of drugs identical to the first composition,
- wherein the therapeutic swab is configured for use in a nasopharynx and a posterior pharynx of a subject.
A therapeutic swab for treating an upper respiratory infection in a subject, the therapeutic swab comprising:
- a stem having a first end and a second end;
- a first drug-loaded swab located at the first end, the first drug-loaded swab consisting of a swab and a first plurality of drugs consisting of:
- brilacidin,
- at least one innate heme oxygenase-1 (HO-1) inducing agent selected from hemin, 4-octyl-itaconate, dimethyl fumarate, and combinations thereof,
- at least one anticoagulant selected from a modified heparin, a low molecular weight heparin (LMWH), chondroitin sulfate (CS), and a modified glycosaminoglycans (GAG) derivative, and
- at least one drug component having anti-inflammatory activity,
- wherein the therapeutic swab is configured for use in a nasopharynx and a posterior pharynx of a subject.
A method of treating an upper respiratory infection in a human subject, the method comprising:
- locally administering a plurality of drugs located on a drug-loaded swab to at least one body region of the subject,
- the at least one body region including the posterior pharynx of the human subject, and
- the plurality of drugs consisting of:
- at least one antiviral agent,
- hemin,
- an anticoagulant selected from a modified heparin, a low molecular weight heparin (LMWH), chondroitin sulfate (CS), and a modified glycosaminoglycans (GAG) derivative, and
- a drug component having anti-inflammatory activity.
Dependencies are inferred from the claim text.